Takeda's exkivity™ (mobocertinib) approved by u.s. fda as the first oral therapy specifically designed for patients with egfr exon20 insertion+ nsclc

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that the u.s. food and drug administration (fda) has approved exkivity (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion mutations as detected by an fda-approved test, whose disease has progressed on or after platinum-based chemo
TAK Ratings Summary
TAK Quant Ranking